S. S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra et al., Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease, Study. Circulation. 25 févr, vol.129, issue.8, p.47, 2010.

A. Hartley, D. C. Marshall, J. D. Salciccioli, M. B. Sikkel, M. Maruthappu et al., Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to, Circulation. 17 mai, vol.133, issue.20, pp.1916-1942, 2009.

W. C. Roberts, A. H. Kragel, and B. N. Potkin, Ages at death and sex distribution in age decade in fatal coronary artery disease, Am J Cardiol. 1 déc, vol.66, pp.1379-81, 1990.

R. B. Schnabel, X. Yin, P. Gona, M. G. Larson, A. S. Beiser et al., 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, The Lancet. 11 juill, vol.386, issue.9989, pp.154-62, 2015.

S. Kralev, K. Schneider, S. Lang, T. Süselbeck, and M. Borggrefe, Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography, PloS One, vol.6, issue.9, p.24964, 2011.

S. Connolly, J. Pogue, R. Hart, M. Pfeffer, and S. Hohnloser, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, ACTIVE Writing Group of the ACTIVE Investigators, vol.367, p.12, 1903.

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med. 15 sept, vol.365, issue.11, pp.981-92, 2011.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med. 8 sept, vol.365, issue.10, p.91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med. 17 sept, vol.361, issue.12, pp.1139-51, 2009.

F. Neumann, M. Sousa-uva, A. Ahlsson, F. Alfonso, A. P. Banning et al.,

. Esc/eacts, Guidelines on myocardial revascularization, Eur Heart J. 25 août, 2018.

I. Iakovou and . Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents, JAMA. 4 mai, vol.293, issue.17, p.2126, 2005.

L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med. 10 sept, vol.361, issue.11, pp.1045-57, 2009.

S. D. Wiviott, E. Braunwald, C. H. Mccabe, G. Montalescot, W. Ruzyllo et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, vol.357, issue.20, p.15, 2001.

S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation, N Engl J Med. 16 août, vol.345, issue.7, p.502, 2001.

N. Sarafoff, A. Martischnig, J. Wealer, K. Mayer, J. Mehilli et al., Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation, J Am Coll Cardiol. mai, vol.61, issue.20, pp.2060-2066, 2013.

A. Schömig, F. J. Neumann, A. Kastrati, H. Schühlen, R. Blasini et al., A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents, N Engl J Med. 25 avr, vol.334, issue.17, pp.1084-1093, 1996.

M. Lamberts, J. B. Olesen, M. H. Ruwald, C. M. Hansen, D. Karasoy et al., Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 4 sept, vol.126, pp.1185-93, 2012.

W. B. Kannel, R. D. Abbott, D. D. Savage, and P. M. Mcnamara, Epidemiologic Features of Chronic Atrial Fibrillation, N Engl J Med. 29 avr, vol.306, issue.17, pp.1018-1040, 1982.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

W. Dewilde, T. Oirbans, F. Verheugt, J. C. Kelder, D. Smet et al., Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet Lond Engl. 30 mars, vol.381, issue.9872, pp.1107-1122, 2013.

C. M. Gibson, R. Mehran, C. Bode, J. Halperin, F. W. Verheugt et al., Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI, N Engl J Med, vol.22, issue.25, pp.2423-2457, 2016.

C. P. Cannon, D. L. Bhatt, J. Oldgren, G. Lip, S. G. Ellis et al., Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation, N Engl J Med, vol.19, issue.16, pp.1513-1537, 2017.

. Authors/task-force-members, S. Windecker, P. Kolh, F. Alfonso, J. Collet et al., ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J, vol.35, issue.37, pp.2541-619, 2014.

C. T. January, L. S. Wann, J. S. Alpert, H. Calkins, J. E. Cigarroa et al., , 2014.

, AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol. 2 déc, vol.64, issue.21, pp.1-76, 2014.

M. Roffi, C. Patrono, J. Collet, C. Mueller, M. Valgimigli et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC), Eur Heart J. 14 janv, vol.37, issue.3, p.315, 2015.

M. Valgimigli, H. Bueno, R. A. Byrne, J. Collet, F. Costa et al., ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J. 14 janv, vol.39, issue.3, p.60, 2017.

G. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen et al., Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J. juin, vol.31, issue.11, pp.1311-1319, 2010.

K. A. Hicks, J. E. Tcheng, B. Bozkurt, B. R. Chaitman, D. E. Cutlip et al., , 2014.

. Acc/aha, Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards), J Am Coll Cardiol. 28 juill, vol.66, issue.4, pp.403-69, 2015.

R. Mehran, S. V. Rao, D. L. Bhatt, C. M. Gibson, A. Caixeta et al., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation. 14 juin, vol.123, issue.23, pp.2736-2783, 2011.

M. Lamberts, G. H. Gislason, J. B. Olesen, S. L. Kristensen, S. Olsen et al., Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention, J Am Coll Cardiol. 10 sept, vol.62, issue.11, pp.981-990, 2013.

H. B. Golwala, C. P. Cannon, P. G. Steg, G. Doros, A. Qamar et al., Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials, Eur Heart J. 14 mai, vol.39, pp.1726-1735, 2018.

J. G. Andrade, M. W. Deyell, C. Khoo, M. Lee, K. Humphries et al., Risk of Bleeding on Triple Antithrombotic Therapy After Percutaneous Coronary Intervention/Stenting: A Systematic Review and Meta-analysis, Can J Cardiol. févr, vol.29, issue.2, p.12, 2013.

K. C. Koskinas, L. Räber, T. Zanchin, T. Pilgrim, S. Stortecky et al., Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention, JACC Cardiovasc Interv, vol.25, issue.14, pp.1473-83, 2016.

D. Lindholm, G. Sarno, D. Erlinge, B. Svennblad, P. Hasvold et al., Association of key risk factors and their combinations on ischemic outcomes and bleeding in patients with invasively managed myocardial infarction in Sweden, Eur Heart J, vol.39, issue.suppl_1, pp.565-1398, 2018.

L. Bonello, L. Camoin-jau, S. Armero, O. Com, S. Arques et al., Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis, Am J Cardiol. 1 janv, vol.103, issue.1, p.10, 2009.

R. Mehran, S. J. Pocock, G. W. Stone, T. C. Clayton, G. D. Dangas et al., Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial, Eur Heart J. 1 juin, vol.30, issue.12, pp.1457-66, 2009.

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet Lond Engl. 15 mars, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

A. L. Dans, S. J. Connolly, L. Wallentin, S. Yang, J. Nakamya et al., Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, Circulation. 5 févr, vol.127, issue.5, p.40, 2013.

J. W. Eikelboom, S. J. Connolly, J. Bosch, G. R. Dagenais, R. G. Hart et al., Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease, N Engl J Med. 05, vol.377, issue.14, p.30, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01892329

J. L. Mega, E. Braunwald, S. D. Wiviott, J. Bassand, D. L. Bhatt et al., Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med. 5 janv, vol.366, issue.1, pp.9-19, 2012.

J. H. Alexander, R. D. Lopes, S. James, R. Kilaru, Y. He et al., Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med. 25 août, vol.365, issue.8, pp.699-708, 2011.

R. D. Lopes, A. N. Vora, D. Liaw, C. B. Granger, H. Darius et al., An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial, Am Heart J. juin, vol.200, pp.17-23, 2018.

M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen, Warfarin, aspirin, or both after myocardial infarction, N Engl J Med. 26 sept, vol.347, issue.13, pp.969-74, 2002.

. Caprie-steering-committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee, Lancet Lond Engl, vol.348, issue.9038, pp.1329-1368, 1996.

M. Gilard, D. Blanchard, G. Helft, D. Carrier, H. Eltchaninoff et al., Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]), Am J Cardiol. 1 août, vol.104, issue.3, p.42, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00913020

M. G. Mennuni, J. L. Halperin, S. Bansilal, M. M. Schoos, K. N. Theodoropoulos et al., Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry), Am J Cardiol. 1 juill, vol.116, issue.1, p.42, 2015.

M. B. Effron and C. M. Gibson, Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy -« Real World » Experience, Prog Cardiovasc Dis. févr, vol.60, issue.4, pp.531-537, 2018.

K. A. Fiedler, M. Maeng, J. Mehilli, S. Schulz-schüpke, R. A. Byrne et al., Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial, J Am Coll Cardiol. 28 avr, vol.65, issue.16, pp.1619-1648, 2015.

U. Baber, S. X. Li, R. Pinnelas, S. J. Pocock, M. W. Krucoff et al., Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients), Circ Cardiovasc Interv. mars, vol.11, issue.3, p.6144, 2018.